GamaMabs Pharma will present new results from its collaboration with the Institut Curie at TAT meeting (Paris, March 2-4 2015) with a poster describing 3C23K antibody efficacy in combination with chemotherapy in PDX models.
Toulouse, France – February 27, 2015 – GamaMabs Pharma, announces the presentation of a poster at the 13th International congress on Targeted Anticancer Therapies (TAT 2015) held in Paris from March 2 to 4, 2015.
The poster « In vivo synergism between chemotherapy and the 3C23K monoclonal antibody targeting the AMH-type II receptor in ovarian cancer PDX models» with F. Nemati and D. Decaudin from Curie Institute as principal authors, and in collaboration with GamaMabs Pharma scientists, is presented during the TAT congress in Paris on the 2nd of March 2015.
It summarizes, in a study performed on 14 ovarian cancer Patient Derived Xenografts (PDX) models, out of which 43% (6 PDX) express AMHR2 detected with three different techniques, that 3C23K increases the anti-tumoral efficacy of conventional first line chemotherapy (carboplatin/paclitaxel) in ovarian cancers. In AMHR2 expressing models, this efficacy translates in an increase of complete response in all arms where the antibody is associated with chemotherapy.
Those results confirm the interest in developing this combination in patients with ovarian cancer expressing AMHR2, cancer which prognostic remains dismal.
GamaMabs Pharma plans the beginning of clinical trials with 3C23K in the second half of 2015.
Jean-François Prost, MD, VP R&D and Strategy GamaMabs Pharma declares « We are proud of this new communication which results confirm the interest of this very specific embryonic target, associated with the fetus sexual development and reappearing in the majority of gynecologic cancers and also in certain testicular cancers ».
Anne Bousseau, MD who joined GamaMabs Pharma team as Senior Advisor Oncology specifies « I’m happy to be part of GamaMabs Pharma team and to participate in this really promising project, very innovative by its target and by the effector cells activation properties of the 3C23K antibody ».
About GamaMabs Pharma
GamaMabs Pharma is a French Biotechnology company developing innovative monoclonal antibodies in cancer. GamaMabs’ lead project is the monoclonal antibody 3C23K, currently in advanced pre-IMPD stage, which targets Anti-Mullerian Human Receptor 2 (AMHRII/MISIIR) in ovarian cancer. Ovarian cancer is responsible for over 50 000 deaths every year in Europe and the United States. The company develops low-fucose antibodies with increased activity through the activation of immune system cells.
For more information: www.gamamabs.com
Jean-François Prost, VP R&D and Strategy, email@example.com